“For years we have been working with these two great institutions, SDA Bocconi and the Italian Society of Neurology,” he explains Giuseppe Banfi, CEO of Biogen Italia, during his speech at the final conference of the two-year project NeuroMLab, (Neurology management Lab) organized by Biogen and SDA Bocconi, with the patronage of the Italian Society of Neurology (Sin), which involved neurologists, nurses, pharmacists, health directors and other players in the health system.
“The role of companies must be this – continues Banfi – face the great challenges of the future in the best possible way, acting as a partner of the institutions, be they scientific, managerial, political or managerial institutions “. Among these challenges there is undoubtedly the treatment of Alzheimer’s, a particularly disabling disease that affects about 700,000 people in Italy and which, with the arrival of new therapeutic aids, will see important changes in its management. In fact, Banfi reiterates this at the end of his speech: “Like Biogen, we not only deal with offering valuable drugs to the scientific community and patients, but also valuable services, aiming at the renewal of management paths in order to optimize the use of resources and improve patient care. We also believe – he concludes – that bringing together different disciplines and knowledge is the best way to create great value for the public health of tomorrow ”.
#Banfi #Biogen #Italia #Companies #partners #institutions #neurological #challenges